The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

Findings from the pivotal study showed patients receiving Vyalev demonstrated superior improvement in motor fluctuations, with increased "on" time without troublesome dyskinesia and decreased "off" ...

The U.S. FDA has approved the first 24-hour continuous subcutaneous infusion for adults with advanced Parkinson’s disease.

Here's a recap of the week’s most important stories.

The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).